olopatadine + fluticasone propionate

A combination of **olopatadine** (an H1-receptor antagonist/antihistamine) and **fluticasone propionate** (a synthetic glucocorticoid corticosteroid) used as a topical (generally intranasal) therapy for the symptomatic relief of **allergic rhinitis** and allergic rhinoconjunctivitis. **Olopatadine** blocks the activity of histamine at H1 receptors, alleviating symptoms such as sneezing, nasal pruritus, and rhinorrhea. **Fluticasone propionate** acts as an anti-inflammatory agent, reducing inflammation by affecting the production and activity of a range of inflammatory cells and mediators, including mast cells, eosinophils, neutrophils, macrophages, lymphocytes, histamine, eicosanoids, leukotrienes, and cytokines[1][2][3]. The combination is intended to provide both rapid antihistaminic effects and broad anti-inflammatory action for nasal and/or ocular allergic symptoms. Currently, the most widely marketed fixed-dose antihistamine/intranasal steroid combinations use **azelastine** rather than olopatadine, and there does not appear to be an FDA-approved fixed product of olopatadine + fluticasone propionate, though both are sometimes used concomitantly in practice or in clinical studies.